On Monday, Shares of Electronic Arts Inc. (NASDAQ:EA), lost -0.03% to $59.31.
On April 21, Electronic Arts, and the UFC® declared that EA SPORTS UFC will be accessible for free download on the App StoreSM and Google Play™. The development team at EA Canada worked in partnership with the EA SPORTS UFC console team, leveraging their codebase to deliver HD-quality visuals, intuitive touch controls and action-packed gameplay. With no limits to how much you can play, gamers are free to climb UFC’s virtual ranks, reaping amazing in-game rewards, unlocking new opponents and knocking out the competition. The game launched two months ago in Canada, South Korea, Singapore and Russia, and has been downloaded over two million times with gamers playing for an average of 36 minutes every day.
“We are really excited about the early fan feedback and support we’ve received, and now even more people around the world can experience the best in class visuals and immersive gameplay that set a new bar for mobile and tablet fighting games,” said Dean Richards, GM, EA SPORTS. “Combined with intuitive touch controls, this is the ultimate vehicle to transport players of all skill levels into the heart of the action, bringing all the emotion and intensity of a fight to life wherever they are.”
“After the success of their first UFC videogame, EA is now giving fans another amazing way to play EA SPORTS UFC, no matter where they are in the world,” UFC President Dana White said. “EA continues to deliver quality gaming experiences and with the mobile game, not only are we going to reach a broader fan base, but we’re making the sport accessible on a global platform.”
Electronic Arts Inc. develops, markets, publishes, and distributes game software content and services for video game consoles, personal computers, mobile phones, and tablets. The company operates through EA Games, EA SPORTS, Maxis, PopCap, and All Play segments.
Shares of bluebird bio, Inc. (NASDAQ:BLUE), declined -1.41% to $136.98, during its last trading session.
bluebird bio, declared that members of the administration team will take part in the following forthcoming health care conferences:
- Deutsche Bank 40th Annual Health Care Conference on Thursday, May 7, 2015 from 8:40 to 9:15 a.m. ET at the Intercontinental Hotel in Boston.
- Bank of America Merrill Lynch 2015 Health Care Conference on Tuesday, May 12, 2015 from 4:20 to 4:50 p.m. PT at the Encore at the Wynn Hotel in Las Vegas.
bluebird bio, Inc., a clinical-stage biotechnology company, focuses on developing transformative gene therapies for severe genetic and rare diseases. Its advanced product candidate is Lenti-D, which is in phase II/III clinical studies for the treatment of childhood cerebral adrenoleukodystrophy, a rare, hereditary neurological disorder affecting young boys; and LentiGlobin that is in phase I/II clinical studies for the treatment of beta-thalassemia major and severe sickle cell disease (SCD) in France, in addition to a phase I study in the United States for the treatment of severe SCD.
Finally, OvaScience, Inc. (NASDAQ:OVAS), ended its last trade with 0.32% gain, and closed at $25.40.
OvaScience, declared the appointment of John E. Sexton, Ph.D., President of New York University (NYU), to the OvaScience Board of Directors.
“John’s leadership has been instrumental in elevating the global recognition of NYU, counting establishing world-class campuses as well as academic and research sites internationally,” said Michelle Dipp, M.D., Ph.D., Chief Executive Officer and Co-Founder of OvaScience. “His personal passion for our mission to bring new fertility treatments to patients and his ability to build successful international operations will be assets to OvaScience as we expand our global presence.”
“I personally understand the difficulty many people face when undergoing in vitro fertilization and why innovations in fertility are so desperately needed,” said Dr. Sexton. “OvaScience’s technology is founded in strong science that has already yielded a new treatment designed to enhance IVF, and I am happy to join the Board as the Company prepares to introduce future fertility treatments to patients.”
OvaScience, Inc., a life science company, engages in the discovery, development, and commercialization of new treatments for infertility. The company’s patented technology is based on the discovery of egg precursor (EggPC) cells, which are immature egg cells found in the protective outer layer of a woman’s own ovaries.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.